Breaking News, Collaborations & Alliances

Iovance Expands Partnership with WuXi Advanced Therapies

WuXi will increase capacity for Iovance's innovaTIL-01 and innovaTIL-04 studies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Iovance Biotherapeutics, a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, has expanded its relationship with WuXi AppTec’s Advanced Therapies Business Unit (WuXi ATU). WuXi will increase capacity for Iovance’s innovaTIL-01 and innovaTIL-04 studies, which offer lifileucel and LN-145 for treatment of metastatic melanoma and recurrent, metastatic, or persistent cervical cancer, respectively.   “We a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters